Supriya Lifescience Limited (SUPRIYA.NS)
INR 638.35
(-1.05%)
INR 638.35
(-1.05%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 50.2 Million INR | -8.54% |
| 2022 | 54.89 Million INR | 3.66% |
| 2021 | 52.95 Million INR | 156.42% |
| 2020 | 20.65 Million INR | -56.09% |
| 2019 | 47.03 Million INR | -55.91% |
| 2018 | 106.66 Million INR | -69.81% |
| 2017 | 353.3 Million INR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | - INR | 0.0% |
| 2024 Q1 | - INR | 100.0% |
| 2023 FY | 50.2 Million INR | -8.54% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q4 | 50.2 Million INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q2 | 52.61 Million INR | 0.0% |
| 2022 Q4 | 54.89 Million INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q2 | 56.7 Million INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 FY | 54.89 Million INR | 3.66% |
| 2021 Q2 | 19.19 Million INR | 0.0% |
| 2021 FY | 52.95 Million INR | 156.42% |
| 2021 Q4 | 52.95 Million INR | 0.0% |
| 2020 Q3 | 21.38 Million INR | 0.0% |
| 2020 FY | 20.65 Million INR | -56.09% |
| 2020 Q4 | 20.65 Million INR | -3.41% |
| 2019 FY | 47.03 Million INR | -55.91% |
| 2018 FY | 106.66 Million INR | -69.81% |
| 2017 FY | 353.3 Million INR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Biocon Limited | 129.32 Billion INR | 99.961% |
| Blue Jet Healthcare Limited | 3.79 Million INR | -1224.538% |
| Concord Biotech Limited | 18.87 Million INR | -166.031% |
| Dishman Carbogen Amcis Limited | 2.45 Billion INR | 97.956% |
| Jubilant Ingrevia Limited | 4.25 Billion INR | 98.82% |
| Lyka Labs Limited | 429.06 Million INR | 88.3% |
| Panacea Biotec Limited | 209.9 Million INR | 76.084% |
| Piramal Pharma Limited | 24.83 Billion INR | 99.798% |
| SMS Lifesciences India Limited | 331.45 Million INR | 84.854% |
| Syngene International Limited | 1 Billion INR | 94.98% |
| TAKE Solutions Limited | 7.5 Million INR | -569.333% |
| Zota Health Care Limited | 631.64 Million INR | 92.052% |